Monthly formulary amendments – July 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in July 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly Horizon Scanning Report – August 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in July 2026.
This information is produced for use by NHS healthcare professionals.
Top 50 BNF sections and drugs
Overview
This report looks at the top 50 BNF sections and drugs in terms of spend at ICB and SICBL level for the financial year to date with a focus on cost growth and item growth.
Frequency
Monthly
Data period
April to June 2026
Drug Tariff Monitor
Overview
The purpose of this report is to present the predicted cost impact of category A, M and C drug tariff PartVIIIA price changes on primary care spending. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at SICBL and ICB level.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Quarterly
Data Period
July 2026 (Drug Tariff), May 2026 (ePACT2 Prescribing data)
Price Concessionary Bulletin
Overview
The purpose of this bulletin is to present the predicted cost impact of drug price changes, both through the Price Concessions list and also monthly drug tariff (DT) cost variations. The data is calculated by matching the ePACT2 prescribing data for the latest month available to the current prices listed in the NHSBSA Drug Tariff PartVIIIA. An adjustment is also made if necessary to the prescribing data of each drug to account for any difference in dispensing days between the 2 months. Data is presented at region, ICB and SICBL level.
If you have any queries about the content of the report please contact us at nuth.nyrdtc.rxsupp@nhs.net
Frequency
Monthly
Data Period
July 2026 (Drug Tariff), May 2026 (ePACT2 prescribing data)
Cost Comparison Charts
Overview
The charts included within this report are organised by BNF classification (legacy) and show comparative costs at the NHS basic price1,2 (as of July 2026) for selected agents. Except where indicated otherwise, each chart shows the cost of 1 year3 of treatment at a commonly prescribed daily dose (shown in brackets). The doses given are not intended to imply therapeutic equivalence and for some BNF sub-classifications, such as angiotensin converting enzyme inhibitors (ACE inhibitors), the doses may vary according to indication. Additionally, in some therapeutic areas, for instance antibacterial drugs, the duration of treatment may differ from that shown. Primarily, this report focuses on costs related to prescribing in adults. There are however a few exceptions where products specifically for use in children are represented, such as in the emollient and Infant formulas sections. Additional notes to highlight any relevant cost related information are also added where appropriate, to improve the clarity of the information presented.
Rationale for inclusion: the cost comparison charts (CCCs) aim to represent the diversity of products available; including the least expensive, most prescribed, higher cost products being prescribed and products with additional features. The products included are furthermore considered in the context of national and local guidance and stakeholder formulary decisions. It is not possible to represent all pharmaceuticals within these charts.
Stakeholders (under password protection) can access the current version of the CCCs via our website in three formats: PDF, Word and Excel. The Excel version incorporates a more detailed comparison of contraceptives and allows charts to be split by BNF subsections in some instances.
References
1. NHS Business Services Authority (NHS BSA). Drug tariff.
2. NHS BSA. Dictionary of medicines and devices (dM+d).
3. 1 year in this instance is equal to 364 days (rather than 365) standardising 1 month as equal to 28 days.
Time Period
July 2026
Frequency
Quarterly
Monthly Horizon Scanning Report – July 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in June 2026.
This information is produced for use by NHS healthcare professionals.
Monthly formulary amendments – June 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in June 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders
Monthly Horizon Scanning Report – June 2026
Monthly horizon scanning reports are designed to inform the NHS about new products, significant changes to product licences, significant new guidance, and decisions that have been made by recognised bodies.
This edition covers new and updated medicines and guidance published in May 2026.
This information is produced for use by NHS healthcare professionals.
Monthly formulary amendments – May 2026
Monthly Formulary Amendments Documents list any NICE Technology Appraisals, NICE Guidelines, MHRA Drug Safety Updates, and National Patient Safety Alerts published in the previous calendar month which may have an impact on local formularies and guidelines. This document is for APCs, and formulary committees to ensure formularies remain up to date, and in line with latest NICE guidance and safety information.
This edition covers guidance and alerts published in May 2026.
It includes a suggested formulary position for APCs/formulary committees, together with a summary of any financial/commissioning implications. The purpose of the document is to support consistent decision making by APCs.
This information is produced for use by NHS healthcare professionals and RDTC stakeholders